simplyStocks
Revvity
RVTY · NYSELife Sciences & Diagnostics
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$11B
P/E ratio
~42×
Div yield
~0.3%
Revenue
~$2.85B
Rev. growth
~+5%
Profit margin
~10%
Segments
2 (LS / Dx)
Employees
~11,000
In plain English
Revvity is the life-sciences-and-diagnostics company carved out of the old PerkinElmer in 2023. Two roughly equal halves: a Life Sciences arm selling reagents, antibodies (BioLegend), automation and lab software (Signals) to drug researchers, and a Diagnostics arm that is a world leader in newborn screening and autoimmune testing (EUROIMMUN) for hospitals and clinical labs.
In simple terms
What Revvity really sells
Revvity is the life-sciences-and-diagnostics company carved out of the old PerkinElmer in 2023. Two roughly equal halves: a Life Sciences arm selling reagents, antibodies (BioLegend), automation and lab software (Signals) to drug researchers, and a Diagnostics arm that is a world leader in newborn screening and autoimmune testing (EUROIMMUN) for hospitals and clinical labs.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?